gradipore anouncement

  1. 3,176 Posts.
    GRADIPORE LIMITED 2003-02-13 ASX-SIGNAL-G

    HOMEX - Sydney

    +++++++++++++++++++++++++
    GRADIPORE ANNOUNCES AGREEMENT WITH HONG KONG'S ADVANTEK BIOLOGICS FOR
    APPLICATION OF GRADIFLOW(TM) TECHNOLOGY FOR BIOSAFETY OF PLASMA
    FRACTIONS

    Deal Provides Gradipore Commercial Introduction Into The Chinese
    Fractionation Market

    Gradipore (ASX Code: GDP) today announced an agreement with Advantek
    Biologics Limited of Hong Kong, China for a three-stage application
    of the company's Gradiflow. separations technology for use in
    intravenous immunoglobulin (IVIG) fractionation.

    After the initial phase of the agreement, Gradipore will send a
    commercial scale Gradiflow unit to Hong Kong for the production of
    blood products. The final phase will involve the potential adoption
    of the Gradiflow technology into a processing plant on the mainland
    of China.

    The deal will generate immediate revenue for Gradipore and may pave
    the way for foreign product and service entry into the lucrative
    China and Asian biological marketplaces.

    Advantek plans to use the Gradiflow separation system to isolate
    plasma proteins especially IVIG from waste streams of current
    technology and also significantly upgrade biosafety issues with
    Gradipore's patented viral removal and prion removal advantages.

    Advantek's incorporation of the Gradiflow separation and isolation
    technology may provide the company with significant safety advantages
    and more accurate separation results when compared to the
    presently-used methods, as well as time and cost advantages through
    increased IVIG yields. Purified IVIG is used for the treatment of
    autoimmune diseases and HIV-infected patients.

    "Recently, there has been an increasing demand for high-quality
    plasma proteins in the Asian market," said Dr. Bing Lou Wong, CEO of
    Advantek Biologics. "Our objective is to become a leading Asian
    provider of plasma products for use in surgical procedures as well as
    treatment of specific diseases." Gradiflow technology has shown
    promising results in its ability to remove bacterial, viral and prion
    contaminants, and Advantek is hopeful that this novel and exciting
    technology can be applied to ensure the safety of our varied plasma
    products and meet stringent regulatory requirements. The higher yield
    and greater biosafety of the Gradiflow process will contribute
    significantly to Advantek producing biological products of superior
    quality."

    The world market for blood products was estimated in early 2000 to be
    US$6.5 billion of which Asia (excluding Japan) represented US$400
    million (7%). It is estimated that the current world market may be
    closer to US$10 billion. The Asian market is growing at an annual
    rate of 15-20%. China represents 47% of the Asian market, which at
    current rates will grow to US$550 million in 2003, US$850 million in
    2005 and US$1.5 billion in 2008.

    "From a marketing standpoint, the Chinese marketplace is a lucrative
    one that has provided significant challenges in terms of
    penetration," said Robert Lieb, Global CEO of Gradipore.

    "This deal is important on two levels. Gradiflow has the potential to
    provide increased yields of Advantek's biologics while enhancing
    biosafety, and operate effectively on an industrial production scale.
    In addition, we are hopeful that the successful completion of this
    agreement will lead to widespread availability of Gradiflow
    technology in the Asian markets, including Hong Kong and Greater
    China."

    ABOUT ADVANTEK BIOLOGICS LIMITED

    Advantek Biologics' biological products, including IVIG, are
    manufactured in compliance with current Good Manufacturing Practice
    (cGMP) guidelines set by US FDA, and are of superior quality and
    highly free of bacterial and viral contaminants. Advantek has
    recently signed an agreement with Amersham Biosciences to develop
    innovative chromatographic production technologies for plasma-derived
    products, including Antithrombin III, Alpha 1 Anti-Trypsin and
    Transferrin.

    For more information on Advantek, visit the company's corporate web
    site at www.Advantekbiologics.com

    ABOUT GRADIPORE

    www.gradipore.com

    Simone Lockwood
    Gradipore Limited
    (02) 8977-9000 Jonathan Revitt

    Porter Novelli
    (02) 8585 8200


 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.